title: Spontaneous atherosclerotic lesions and prostacyclin formation in rabbits: effects of combined dipyridamole and aspirin.
abstract: The influence of dipyridamole and lysine acetylsalicylate on the incidence of atherosclerotic lesions and on arterial prostacyclin formation was studied in rabbits. Male New Zealand rabbits received i.m. for 16 months dipyridamole (12.5 mg/kg/day) and lysine acetylsalicylate (0.5 mg/kg/day). The incidence of spontaneous atherosclerotic lesions in the aorta was reduced by 16.4% with respect to untreated animals. Administration of the drugs significantly increased prostacyclin formation with respect to the untreated rabbits both in animals developing (1124 +/- 197 pg/mg/3 min vs 316 +/- 49 pg/mg/3 min) or not developing lesions (499 +/- 40 pg/mg/3 min vs 246 +/- 19 pg/mg/3 min). The observed increase in prostacyclin formation could account for the lowered incidence of atherosclerotic lesions in rabbits receiving the combination of dipyridamole and lysine acetylsalicylate.
authors.affiliation: Services of Hematology and Pathologic Anatomy, San Millán Hospital, Logroño, Spain.
authors.forename: J
authors.initials: J
authors.lastname: Lasierra
authors.forename: J
authors.initials: J
authors.lastname: Gonzalez
authors.forename: M J
authors.initials: MJ
authors.lastname: Aza
authors.forename: J
authors.initials: J
authors.lastname: Melon
authors.forename: E
authors.initials: E
authors.lastname: Vazquez
authors.forename: P S
authors.initials: PS
authors.lastname: Collado
authors.forename: C
authors.initials: C
authors.lastname: Castellarnau
authors.forename: M
authors.initials: M
authors.lastname: Rutllant
mesh_terms: D015121:6-Ketoprostaglandin F1 alpha / Q000096:biosynthesis*; D000818:Animals; D001011:Aorta / Q000473:pathology; D001158:Arteries / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D001161:Arteriosclerosis / Q000473:pathology / Q000517:prevention & control*; D001241:Aspirin / Q000008:administration & dosage / Q000627:therapeutic use*; D004176:Dipyridamole / Q000008:administration & dosage / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D011464:Epoprostenol / Q000096:biosynthesis*; D066298:In Vitro Techniques; D008297:Male; D009131:Muscle, Smooth, Vascular / Q000378:metabolism*; D011817:Rabbits
chemical_list: D015121:6-Ketoprostaglandin F1 alpha; D004176:Dipyridamole; D011464:Epoprostenol; D001241:Aspirin